Cargando…

Volatile organic compounds emitted from faeces as a biomarker for colorectal cancer

BACKGROUND: Colorectal cancer remains a leading cause of mortality and morbidity. The UK Bowel Cancer Screening Programme (BCSP) has demonstrated that detection of colorectal cancer at an earlier stage and identification of advanced pre‐malignant adenomas reduces mortality and morbidity. AIM: To ass...

Descripción completa

Detalles Bibliográficos
Autores principales: Bond, Ashley, Greenwood, Rosemary, Lewis, Stephen, Corfe, Bernard, Sarkar, Sanchoy, O'Toole, Paul, Rooney, Paul, Burkitt, Michael, Hold, Georgina, Probert, Chris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593415/
https://www.ncbi.nlm.nih.gov/pubmed/30828825
http://dx.doi.org/10.1111/apt.15140
_version_ 1783430040500830208
author Bond, Ashley
Greenwood, Rosemary
Lewis, Stephen
Corfe, Bernard
Sarkar, Sanchoy
O'Toole, Paul
Rooney, Paul
Burkitt, Michael
Hold, Georgina
Probert, Chris
author_facet Bond, Ashley
Greenwood, Rosemary
Lewis, Stephen
Corfe, Bernard
Sarkar, Sanchoy
O'Toole, Paul
Rooney, Paul
Burkitt, Michael
Hold, Georgina
Probert, Chris
author_sort Bond, Ashley
collection PubMed
description BACKGROUND: Colorectal cancer remains a leading cause of mortality and morbidity. The UK Bowel Cancer Screening Programme (BCSP) has demonstrated that detection of colorectal cancer at an earlier stage and identification of advanced pre‐malignant adenomas reduces mortality and morbidity. AIM: To assess the utility of volatile organic compounds as a biomarker for colorectal neoplasia. METHODS: Faeces were collected from symptomatic patients and people participating in the UK BCSP, prior to colonoscopy. Headspace extraction followed by gas chromatography mass spectrometry was performed on faeces to identify volatile organic compounds. Logistic regression modelling and 10‐fold cross‐validation were used to test potential biomarkers. RESULTS: One hundred and thirty‐seven participants were included (mean age 64 years [range 22‐85], 54% were male): 60 had no neoplasia, 56 had adenomatous polyp(s) and 21 had adenocarcinoma. Propan‐2‐ol was significantly more abundant in the cancer samples (P < 0.0001, q = 0.004) with an area under ROC (AUROC) curve of 0.76. When combined with 3‐methylbutanoic acid the AUROC curve was 0.82, sensitivity 87.9% (95% CI 0.87‐0.99) and specificity 84.6% (95% CI 0.65‐1.0). Logistic regression analysis using the presence/absence of specific volatile organic compounds, identified a three volatile organic compound panel (propan‐2‐ol, hexan‐2‐one and ethyl 3‐methyl‐ butanoate) to have an AUROC of 0.73, with a person six times more likely to have cancer if all three volatile organic compounds were present (P < 0.0001). CONCLUSIONS: Volatile organic compound analysis may have a superior diagnostic ability for the identification of colorectal adenocarcinoma, when compared to other faecal biomarkers, including those currently employed in UK. Clinical trial details: National Research Ethics Service Committee South West ‐ Central Bristol (REC reference 14/SW/1162) with R&D approval from University of Liverpool and Broadgreen University Hospital Trust (UoL 001098).
format Online
Article
Text
id pubmed-6593415
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-65934152019-07-10 Volatile organic compounds emitted from faeces as a biomarker for colorectal cancer Bond, Ashley Greenwood, Rosemary Lewis, Stephen Corfe, Bernard Sarkar, Sanchoy O'Toole, Paul Rooney, Paul Burkitt, Michael Hold, Georgina Probert, Chris Aliment Pharmacol Ther Faecal Volatile Compounds as a Biomarker for Colorectal Neoplasia BACKGROUND: Colorectal cancer remains a leading cause of mortality and morbidity. The UK Bowel Cancer Screening Programme (BCSP) has demonstrated that detection of colorectal cancer at an earlier stage and identification of advanced pre‐malignant adenomas reduces mortality and morbidity. AIM: To assess the utility of volatile organic compounds as a biomarker for colorectal neoplasia. METHODS: Faeces were collected from symptomatic patients and people participating in the UK BCSP, prior to colonoscopy. Headspace extraction followed by gas chromatography mass spectrometry was performed on faeces to identify volatile organic compounds. Logistic regression modelling and 10‐fold cross‐validation were used to test potential biomarkers. RESULTS: One hundred and thirty‐seven participants were included (mean age 64 years [range 22‐85], 54% were male): 60 had no neoplasia, 56 had adenomatous polyp(s) and 21 had adenocarcinoma. Propan‐2‐ol was significantly more abundant in the cancer samples (P < 0.0001, q = 0.004) with an area under ROC (AUROC) curve of 0.76. When combined with 3‐methylbutanoic acid the AUROC curve was 0.82, sensitivity 87.9% (95% CI 0.87‐0.99) and specificity 84.6% (95% CI 0.65‐1.0). Logistic regression analysis using the presence/absence of specific volatile organic compounds, identified a three volatile organic compound panel (propan‐2‐ol, hexan‐2‐one and ethyl 3‐methyl‐ butanoate) to have an AUROC of 0.73, with a person six times more likely to have cancer if all three volatile organic compounds were present (P < 0.0001). CONCLUSIONS: Volatile organic compound analysis may have a superior diagnostic ability for the identification of colorectal adenocarcinoma, when compared to other faecal biomarkers, including those currently employed in UK. Clinical trial details: National Research Ethics Service Committee South West ‐ Central Bristol (REC reference 14/SW/1162) with R&D approval from University of Liverpool and Broadgreen University Hospital Trust (UoL 001098). John Wiley and Sons Inc. 2019-03-03 2019-04 /pmc/articles/PMC6593415/ /pubmed/30828825 http://dx.doi.org/10.1111/apt.15140 Text en © 2019 The Authors. Alimentary Pharmacology & Therapeutics Published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Faecal Volatile Compounds as a Biomarker for Colorectal Neoplasia
Bond, Ashley
Greenwood, Rosemary
Lewis, Stephen
Corfe, Bernard
Sarkar, Sanchoy
O'Toole, Paul
Rooney, Paul
Burkitt, Michael
Hold, Georgina
Probert, Chris
Volatile organic compounds emitted from faeces as a biomarker for colorectal cancer
title Volatile organic compounds emitted from faeces as a biomarker for colorectal cancer
title_full Volatile organic compounds emitted from faeces as a biomarker for colorectal cancer
title_fullStr Volatile organic compounds emitted from faeces as a biomarker for colorectal cancer
title_full_unstemmed Volatile organic compounds emitted from faeces as a biomarker for colorectal cancer
title_short Volatile organic compounds emitted from faeces as a biomarker for colorectal cancer
title_sort volatile organic compounds emitted from faeces as a biomarker for colorectal cancer
topic Faecal Volatile Compounds as a Biomarker for Colorectal Neoplasia
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593415/
https://www.ncbi.nlm.nih.gov/pubmed/30828825
http://dx.doi.org/10.1111/apt.15140
work_keys_str_mv AT bondashley volatileorganiccompoundsemittedfromfaecesasabiomarkerforcolorectalcancer
AT greenwoodrosemary volatileorganiccompoundsemittedfromfaecesasabiomarkerforcolorectalcancer
AT lewisstephen volatileorganiccompoundsemittedfromfaecesasabiomarkerforcolorectalcancer
AT corfebernard volatileorganiccompoundsemittedfromfaecesasabiomarkerforcolorectalcancer
AT sarkarsanchoy volatileorganiccompoundsemittedfromfaecesasabiomarkerforcolorectalcancer
AT otoolepaul volatileorganiccompoundsemittedfromfaecesasabiomarkerforcolorectalcancer
AT rooneypaul volatileorganiccompoundsemittedfromfaecesasabiomarkerforcolorectalcancer
AT burkittmichael volatileorganiccompoundsemittedfromfaecesasabiomarkerforcolorectalcancer
AT holdgeorgina volatileorganiccompoundsemittedfromfaecesasabiomarkerforcolorectalcancer
AT probertchris volatileorganiccompoundsemittedfromfaecesasabiomarkerforcolorectalcancer